Food, Drugs, and Tech—100 Years of Public Health

Episode Summary

Executive Summary: FDA Principal Commissioner Amy Abernathy argues the agency is more relevant than ever as medicine, food, and software rapidly evolve. She outlines how FDA is modernizing from paper-based workflows to digital, data-driven regulation while preserving its core mission: ensuring safety, effectiveness, and public confidence amid gene editing, AI, real-world evidence, drug shortages, and food-safety challenges.

Main Topics: FDA’s enduring mission and relevance (Priority: 5/5): Abernathy frames the FDA as a century-old consumer protection agency whose role remains essential in an era of accelerating biomedical innovation and public-health risk. Modernizing FDA infrastructure and data intake (Priority: 5/5): The conversation focuses on moving from PDFs, paper, and static submissions to structured digital data, better systems, and an FDA built for continuous surveillance and review at scale. Risk-based regulation and regulatory flexibility (Priority: 5/5): Abernathy explains that FDA must balance safety, public confidence, urgency, and innovation by matching the rigor of review to the risk of the product and context. Emerging therapies: CRISPR, cell therapy, and N-of-1 medicine (Priority: 4/5): They discuss how gene editing, CAR-T, and personalized therapies challenge traditional clinical-development models while still fitting within FDA’s framework for evidence, safety, and manufacturing quality. Algorithms, software as a medical device, and privacy (Priority: 4/5): The discussion covers regulating adaptive algorithms, the need for update-friendly oversight, and the growing privacy challenge posed by re-identifiable health data. Crisis detection: drug shortages, opioids, and foodborne outbreaks (Priority: 4/5): Abernathy highlights FDA’s quiet work to prevent crises before they become public, including forecasting shortages, addressing opioid harm within its authorities, and tracing outbreaks with genomic tools. Future of food safety and synthetic biology (Priority: 3/5): The interview ends with cultured meat, labeling, USDA/FDA jurisdiction, whole-genome sequencing for outbreak tracing, blockchain-based traceability, and the FDA’s ‘Smarter Food Safety’ agenda.

Key Arguments: FDA is still essential because rapidly emerging biology and technology increase, rather than reduce, the need for objective safety and effectiveness review. Modern regulation requires structured digital data, not just electronic PDFs, so FDA can review faster and monitor products continuously. The agency must use risk-based scientific decision-making to right-size review based on product risk, population impact, and public-health consequences. Innovation should be enabled, but only with flexible regulatory paradigms, clear authority, and strong confidence-building evidence. Traditional clinical phases are blurring; phase-one trials may expand, platform trials are growing, and real-world evidence can contribute to a total evidence package. Personalized or N-of-1 therapies are not unprecedented; medicine has long evolved from individualized care toward population-scale methods and can now re-adapt. Algorithms and software need a regulatory framework that can handle rapid updates without requiring full re-review every time a model changes. Much of the privacy framework in HIPAA is outdated for modern genomics and longitudinal health data, which can often be re-identified. FDA can reduce harm from crises even when the public never hears about them, such as averting drug shortages before they occur. Food safety is becoming a data-and-genomics problem, with whole-genome sequencing and supply-chain tracing improving outbreak response and accountability.

Data Points: FDA founding year: 1906 - Commissioner frames FDA as a century-old agency created during a prior industrial revolution. Age of FDA at time of interview: 113 years - Hannah references the agency’s age as a starting point for the discussion. FDA share of international GDP regulated: about 20% - Abernathy says FDA regulates a very large cross-section of global commerce through food, drugs, devices, cosmetics, and other products. Imported food share: about 15% - She notes that roughly 15% of U.S. food is imported and must be inspected for safety and legality. Drug shortages in 2018: north of 50 - Abernathy cites the number of reported drug shortages FDA faced in 2018. Drug shortages averted: over 160 - FDA’s shortage-prevention work reportedly helped avert more shortages than actually occurred. Daily foodborne-outbreak meeting time: 9 a.m. - She describes a standing morning call to monitor and respond to emerging food-safety concerns. PREDICT program age: 10 years old - FDA’s border-inspection rules engine is described as a decade-old system in need of modernization. 21st Century Cures enactment: December 2016 - Abernathy points to the law as a key accelerator for modern clinical-evidence development. HITECH Act stimulus-era timing: circa 2009 - She links the stimulus bill and HITECH to the broad rollout of electronic health records.

Pivotal Quotes: "the need to make sure that we have an objective way of assessing safety and effectiveness and providing consumer confidence that this treatment is appropriate for me is a responsibility to the FDA that actually has more responsibility, not less." — Amy Abernathy: Explaining why FDA remains relevant during a new industrial revolution in biology and medicine. "we need to receive more and more of those applications in digital formats that start to represent structured data, structured data that we can review at scale" — Amy Abernathy: Describing the agency’s modernization agenda for submissions, review, and surveillance. "we are living in a space that gets closer and closer to customized or individualized therapies" — Amy Abernathy: Framing the shift toward CRISPR, CAR-T, and other personalized medical interventions.

Implications: FDA will need to become more digital, more adaptive, and more data-literate while keeping trust intact. For industry, this means clearer evidence frameworks, smarter trials, and stronger privacy/security expectations.